Patient-derived Organoids of Lung Cancer to Test Drug Response

Recruiting now

Conditions studied: Lung Cancer, Organoid

In brief

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.

Key facts

Study ID

NCT03979170

Run by

University Hospital, Geneva

People needed

50

Starts

2019-04-01

Expected to finish

2029-12-30

Last updated by the study team

2024-06-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven lung cancer
• Age ≥ 18
• Written informed and signed consent
• Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

You may not qualify if…

• Less than 18 years of age
• Not able to give informed consent (language, intellectual capacities, etc.)
• Not accessible to biopsy and/or surgery sample
• Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.

Where it is running

• Geneva University Hospitals — Geneva, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.